Endurance Wealth Management Inc. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,987 shares of the medical research company’s stock after selling 526 shares during the period. Thermo Fisher Scientific accounts for about 3.3% of Endurance Wealth Management Inc.’s holdings, making the stock its 5th biggest holding. Endurance Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $17,296,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. State Street Corp increased its holdings in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,337,869 shares of the medical research company’s stock valued at $5,310,745,000 after purchasing an additional 224,799 shares during the last quarter. Geode Capital Management LLC grew its holdings in Thermo Fisher Scientific by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 5,540,921 shares of the medical research company’s stock valued at $1,795,964,000 after buying an additional 151,622 shares in the last quarter. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $1,411,603,000. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Thermo Fisher Scientific by 30.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,217,273 shares of the medical research company’s stock worth $628,819,000 after acquiring an additional 519,525 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,871,942 shares of the medical research company’s stock valued at $608,138,000 after acquiring an additional 26,617 shares during the last quarter. 88.68% of the stock is currently owned by hedge funds and other institutional investors.
Thermo Fisher Scientific stock traded up $4.51 during midday trading on Friday, reaching $340.26. 1,097,619 shares of the stock traded hands, compared to its average volume of 1,572,086. The firm has a market cap of $132.60 billion, a PE ratio of 37.31, a price-to-earnings-growth ratio of 2.25 and a beta of 1.04. The company has a current ratio of 2.32, a quick ratio of 1.69 and a debt-to-equity ratio of 0.67. The company has a 50-day simple moving average of $324.75 and a two-hundred day simple moving average of $317.43. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $351.86.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, June 12th. This represents a $0.88 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.13%.
In other Thermo Fisher Scientific news, COO Mark Stevenson sold 25,000 shares of the stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $328.03, for a total value of $8,200,750.00. Following the sale, the chief operating officer now owns 73,538 shares of the company’s stock, valued at approximately $24,122,670.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total value of $9,990,600.00. Following the completion of the sale, the chief executive officer now directly owns 304,946 shares in the company, valued at approximately $101,553,116.92. The disclosure for this sale can be found here. Insiders own 0.45% of the company’s stock.
A number of brokerages have commented on TMO. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $340.00 to $341.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. BTIG Research upped their price objective on Thermo Fisher Scientific from $342.00 to $372.00 and gave the company an “in-line” rating in a report on Friday, January 31st. Needham & Company LLC raised their target price on Thermo Fisher Scientific from $341.00 to $383.00 in a research note on Thursday, April 23rd. Argus reaffirmed a “positive” rating and issued a $370.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, February 24th. Finally, Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $347.21.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: Mutual funds are not immune from market timing
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.